• Veryan (West Sussex, UK) reported new data for the BioMimics 3-D demonstrated an excellent safety profile and promising clinical performance at both six and twelve months in the treatment of patients with peripheral arterial disease (PAD) undergoing femoropopliteal artery intervention. The MIMICS study compares the safety and efficacy of the BioMimics 3-D stent with a straight nitinol stent (primarily the Bard LifeStent) in patients with PAD undergoing femoropopliteal artery intervention. The BioMimics 3-D stent features a unique design with curvature that closely mimics the natural helical geometry of the human vascular system. This stent is designed to improve blood flow, potentially conferring a vasoprotective effect, and enhances bio-mechanical performance, to reduce kinking, deformation and subsequent vessel trauma during leg flexion, compared to a standard straight nitinol stent. Veryan says its BioMimics 3-D stent technology involves adapting traditional straight stent designs to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3-D technology is designed to enhance clinical performance by improving flow conditions in, and bio-mechanical performance of, stented vessels.

• Vigilant Biosciences (Miami), the maker of the "rinse and spit" screening test for the early detection of oral cancer, reported the completion of a clinical study of new technology designed for early detection of oral cancer developed at the University of Miami Miller School of Medicine and exclusively licensed to VigilantBIO. The study of 300 subjects used a case-control design that ensured cases (oral cancer patients) and controls (volunteers without cancer) were similar with respect to other important factors such as tobacco and alcohol use, age and race. The product consists of a low-cost, oral cancer-specific oral rinse test strip that provides an immediate and simple color change in the presence of certain levels of proteins clinically proven to be associated with early onset of oral cancer – typically before a lesion is even visually detected with a screening aid. Dental offices and public health screening facilities are seen as primary initial markets for the technology. The test targets smokers, drinkers and people with human papillomavirus. The VigilantBIO oral cancer screening technology measures early cancer markers via a saline solution that is swished in the mouth and collected in a tube.

• VuCOMP (Plano, Texas) has received FDA premarket approval (PMA) for Version 2 of its M-Vu CAD system for digital mammography. M-Vu CAD is designed to provide an unprecedented level of performance to help radiologists find breast cancer earlier. FDA guidelines now recommend comprehensive reader studies proving that radiologists are more effective when they use CAD. The company said that the M-Vu system is the only FDA-approved mammography CAD product that meets these recommendations.

No Comments